Cardax

Cardax, Inc. is developing orally bioavailable anti-inflammatory compounds with robust safety for major unmet medical needs. $CDXI

[Cardax @cardaxpharma]

Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded Study: https://t.co/6Fl0FxLRHY

[Cardax @cardaxpharma]

Cardax Refocuses on ZanthoSyn® Consumer Health Business: https://t.co/4UjMiwGPJk

[Cardax @cardaxpharma]

Cardax ($CDXI) Voluntarily Suspends SEC Reporting Obligations: https://t.co/0UPlWdEpC6

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q1 2021 Results https://t.co/SlTV5F8nEe

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports 2020 Results https://t.co/8w47rEJY3q

[US Capital Global @USCapGlobal]

US Capital Global Securities Launches $10MM Convertible Preferred Stock Offering for Cardax, Inc.

Learn more: https://t.co/fV3IEFv4mw

#Health #HealthTech #pharmaceuticals #biopharmaceutical #cardiovascular #inflammation #disease #business #funding #finance #investment #news

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q3 2020 Results: https://t.co/FUWRgcFAHO

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q2 2020 Results: https://t.co/FpVIS1z1G4

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q1 2020 Results: https://t.co/txpMzNm8LM

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports 2019 Annual Results: https://t.co/LXbMcSd8Kf

[Cardax @cardaxpharma]

Coronavirus Disease 2019 (COVID-19) can induce an extreme immune response; this association between infection and progression of disease with inflammation suggests a strategy that would partner anti-infective agents, with anti-inflammatory agents: https://t.co/a5RaaV0WU9

[Cardax @cardaxpharma]

Cardax ($CDXI) Releases White Paper on the Potential Role of Astaxanthin in the Treatment of Coronavirus Disease: https://t.co/96C7LEIHD6 #covid19 #coronavirus #astaxanthin

[Cardax @cardaxpharma]

Cardax ($CDXI) Announces Reverse Stock Split of Common Stock: https://t.co/7T7l9oCA5n

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q3 2019 Results: https://t.co/qVphDMLhWh

[Cardax @cardaxpharma]

Cardax ($CDXI) Announces Interim Results from CHASE Clinical Trial; Interim Review Demonstrates Beneficial Changes in Key Markers of Cardiovascular Health: https://t.co/SXf4j0ogeF

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports Q2 2019 Results: https://t.co/18gyvegj0Y

[Cardax @cardaxpharma]

Cardax ($CDXI) Files Registration Statement for Proposed $15 Million Follow-On Offering: https://t.co/aw3oH3O8Kt

[Cardax @cardaxpharma]

Cardax Reports Q1 2019 Results with Continued Progress Across its ZanthoSyn® Consumer Health Business, CHASE Human Clinical Trial, and Rx Development Programs: https://t.co/ooJwsGsjQx

[Cardax @cardaxpharma]

Cardax ($CDXI) Reports 2018 Results. Revenues from Cardax's ZanthoSyn® more than doubled; CHASE clinical trial initiated; pharmaceutical development plans for CDX-101 and CDX-301 are underway: https://t.co/imhnIpz5wm

[Cardax @cardaxpharma]

Cardax CEO David G. Watumull will present at #NobleConXV on Monday, January 28, 2019 at 11:30 AM ET: https://t.co/ovpnjxJn6r $CDXI